

1 **Bad company? The pericardium microbiome in people investigated for tuberculosis**
2 **pericarditis in an HIV-prevalent setting**

3

4 Georgina Nyawo^{1,2†}, Charissa Naidoo^{1,2†}, Benjamin G. Wu^{3,4}, Benjamin Kwok³, Jose C.
5 Clemente⁵, Yonghua Li³, Stephanie Minnies¹, Byron Reeve¹, Suventha Moodley^{1,2},
6 Thadathilankal-Jess John^{6,7}, Sumanth Karamchand⁷, Shivani Singh³, Alfonso Pecararo⁷,
7 Anton Doubell⁷, Charles Kyriakakis⁸, Robin Warren¹, Leopoldo N. Segal³, Grant Theron^{1,2#}

8 †Contributed equally

9

10 **Running title:** Pericardium microbiome in tuberculosis

11

12 **Affiliations:**

13 ¹DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African
14 Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology
15 and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University,
16 Cape Town, South Africa;

17 ²African Microbiome Institute, Faculty of Medicine and Health Sciences, Stellenbosch
18 University, Cape Town, South Africa;

19 ³Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New
20 York University School of Medicine, New York, USA;

21 ⁴Division of Pulmonary and Critical Care, Veterans Affairs New York Harbor Healthcare
22 System, New York, NY, USA;

23 ⁵Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,
24 New York, USA;

25 ⁶Panorama Mediclinic, Cape Town, South Africa;

26 ⁷Department of Medicine, Division of Cardiology, Stellenbosch University & Tygerberg
27 Academic Hospital, Cape Town, South Africa;

28 ⁸Life Vincent Pallotti Hospital, Cape Town, South Africa.

29

30 **#Corresponding author:**

31 Professor Grant Theron, 2nd Floor BMRI Building, Division of Molecular Biology and Human
32 Genetics, Faculty of Medicine and Health Sciences, Francie Van Zijl Drive, Tygerberg, South
33 Africa, 7505.

34 E-mail: gtheron@sun.ac.za

35 Telephone: +27 21 938 9693

36

37 **Keywords:** pericarditis, extrapulmonary tuberculosis, microbiome, HIV

38 **Abstract**

39 **Background:** The microbiome likely plays a role in tuberculosis (TB) pathogenesis. We
40 evaluated the site-of-disease microbiome and predicted metagenome in people with
41 presumptive tuberculous pericarditis, a major cause of mortality, and explored for the first
42 time, the interaction between its association with C-reactive protein (CRP), a potential
43 diagnostic biomarker and the site-of-disease microbiome in extrapulmonary TB.

44 **Methods:** People with effusions requiring diagnostic pericardiocentesis (n=139) provided
45 background sampling controls and pericardial fluid (PF) for 16S rRNA gene sequencing
46 analysed using QIIME2 and PICRUSt2. Blood was collected to measure CRP.

47 **Results:** PF from people with definite (dTb, n=91), probable (pTB, n=25), and non- (nTB,
48 n=23) tuberculous pericarditis differed in β -diversity. dTBs were, vs. nTBs, *Mycobacterium*-,
49 *Lacticigenium*-, and *Kocuria*-enriched. Within dTBs, HIV-positives were *Mycobacterium*-,
50 *Bifidobacterium*-, *Methylobacterium*-, and *Leptothrix*-enriched vs. HIV-negatives and HIV-
51 positive dTBs on ART were *Mycobacterium*- and *Bifidobacterium*-depleted vs. those not on
52 ART. Compared to nTBs, dTBs exhibited short-chain fatty acid (SCFA) and mycobacterial
53 metabolism microbial pathway enrichment. People with additional non-pericardial
54 involvement had differentially PF taxa (e.g., *Mycobacterium*-enrichment and *Streptococcus*-
55 depletion associated with pulmonary infiltrates). *Mycobacterium* reads were in 34% (31/91),
56 8% (2/25) and 17% (4/23) of dTBs, pTBs, and nTBs, respectively. β -diversity differed
57 between patients with CRP above vs. below the median value (*Pseudomonas*-depleted).
58 There was no correlation between enriched taxa in dTBs and CRP.

59 **Conclusions:** PF is compositionally distinct based on TB status, HIV (and ART) status and
60 dTBs are enriched in SCFA-associated taxa. The clinical significance of these findings,
61 including mycobacterial reads in nTBs and pTBs, requires evaluation.

62 Introduction

63 The burden of tuberculosis (TB) is severe in sub-Saharan Africa, where HIV is frequent¹. In
64 2021, South Africa reported >300 000 incident TB cases and 61 000 deaths¹. About 16% of
65 incident cases are extrapulmonary, affecting sites outside the lungs². Extrapulmonary TB
66 (EPTB) has high fatality, especially in people living with HIV (PLHIV)³. Tuberculous
67 pericarditis (TBP) is an especially severe manifestation, and the deadliest manifestation of
68 EPTB, with up to 40% mortality⁴⁻⁶.

69

70 Immune responses to *Mycobacterium tuberculosis* complex (*Mtb*) involve a cascade of
71 events that are, in part, influenced by the microbiome and their metabolites^{7 8}. For instance,
72 gut enrichment with specific anaerobes (*Anaerostipes*, *Blautia*, *Erysipelotrichaceae*)
73 independently predicts activation of host inflammatory immune pathways and active
74 pulmonary TB compared to sick controls^{9 10}. In PLHIV on ART, greater microbially-derived
75 short chain fatty acid (SCFA; butyrate, propionate) concentrations in the lower airways
76 independently predict incident TB¹¹. When SCFAs are added at physiological
77 concentrations to alveolar macrophages *ex vivo*, there are reductions in macrophage-
78 mediated *Mtb* kill¹¹.

79

80 C-reactive protein (CRP) is a non-specific blood inflammatory marker for triage¹², especially
81 in PLHIV in primary care, where it is WHO-recommended¹³. In studies where CRP was co-
82 analysed with the microbiome, CRP negatively correlated with abundances of anti-
83 inflammatory-associated gut microbiota¹⁴ such as *Faecalibacterium*¹⁵, *Lactobacillus* and
84 *Bifidobacterium*¹⁶. In COVID-19 patients, CRP correlated with potentially pathogenic bacteria
85 such as *Klebsiella* spp. and *Enterococcus* spp.¹⁷ However, the relationship between CRP
86 and the site-of-disease microbiota in presumptive TBP has not been studied.

87

88 Little is known about the microbiome of the pericardial space, especially in the context of
89 EPTB, a major cause of pericardial disease. Previous research has hinted at the influence of

90 microbiota on TB, making it a promising treatment avenue⁷⁻⁹. Our work showed the presence
91 of distinctive microbial communities at the site of disease in people with presumptive
92 tuberculous lymphadenitis¹⁸. Importantly, these communities differed by TB status (definite-,
93 probable- or non-TB) and clinical characteristics, with specific community states (i.e.,
94 *Mycobacterium*-dominated lymphotype) being associated with more severe disease¹⁸.

95

96 Together, this can aid in the identification of novel biomarkers at the microbial-host interface
97 that leads to strategies like host-directed therapies for TB prevention and treatment,
98 including in PLHIV. This could also enhance our understanding of severe inflammation in
99 EPTB, which partly contributes to its high morbidity and mortality. Understanding interactions
100 in the microbiome, together with correlations with CRP can help find meaningful networks via
101 which microbes and host interact, and this can help uncover novel associations and
102 mechanisms.

103

104 We therefore evaluated the site-of-disease microbiome and its predicted metagenome in
105 people investigated for TBP (including PLHIV) as well as whether CRP as a surrogate for
106 inflammation correlates with specific taxa. This work will help provide foundational data on
107 the microbiome's role in TBP.

108 **Methods**

109 *Recruitment and follow-up*

110 People with presumed TB pericarditis referred to Tygerberg Academic Hospital in Cape
111 Town, South Africa for routine diagnostic investigation including pericardiocentesis were
112 recruited between 24 November 2016 and 9 April 2021. Eligible people were ≥ 18 years old
113 and not on TB treatment for ≥ 2 weeks. Demographic, clinical, and chest X-ray (CXR) data
114 were collected. People with TBP were managed by the overseeing clinician in line with
115 current guidelines for the management and treatment of pericardial effusions, and assessed
116 by telephonic follow-up after a minimum of 12 weeks. The study had no role in patient
117 management.

118

119 *Ethics*

120 All people provided written informed consent. The study was approved by the Stellenbosch
121 University Health Research and Ethical Committee (HREC, N16/04/050), Tygerberg
122 Academic Hospital, and the Western Cape Department of Health (WC_2016RP15_762).

123

124 *Specimen collection and processing*

125 Two sampling controls were collected per person: a skin swab of the sterilised puncture site
126 and a sterile saline (Ysterplaat Medical Supplies, South Africa) flush of the vascular sheath
127 prior to pericardiocentesis (background control). At least 4mL pericardial fluid (PF) was
128 collected once sufficient volumes were obtained for routine diagnostic testing. Samples were
129 stored at -80°C until batched DNA extraction. Peripheral blood was collected in serum-
130 separating tubes (SST tubes; BD), and centrifuged ($2054g$, 10 min) within four hours of
131 collection, and serum stored at -80°C . Further details on specimen collection and
132 microbiological testing is in the **Supplementary material**.

133

134 *Patient classification*

135 We designated people as definite tuberculous pericarditis (dTb), probable tuberculous
136 pericarditis (pTb), or non-tuberculous pericarditis (nTb) per **Table S1**¹⁹. People were
137 classified as dTbs if they were positive for acid-fast bacilli by Ziehl-Neelsen smear
138 microscopy and/or had at least one MTB-positive specimen by Mycobacteria Growth
139 Indicator Tube (MGIT) 960 liquid culture (BD Diagnostics, USA), Xpert MTB/RIF (Xpert;
140 Cepheid, USA) and/or Xpert MTB/RIF Ultra (Ultra; Cepheid, USA). pTbs did not meet dTb
141 criteria, had no alternative diagnosis, and were empirically prescribed TB therapy. nTbs had
142 no microbiological evidence of TB and were not placed on treatment.

143

144 *Laboratory procedures*

145 The PureLink Microbiome DNA Purification Kit (Invitrogen, USA) was used for PF, skin
146 swabs and, for efficiency, 1 in 5 background samples. The 16S rRNA gene V4 hypervariable
147 region (150 bp read length, paired-end) was amplified and underwent Illumina MiSeq
148 sequencing¹¹. Further detail is in the **Supplementary Material**. CRP was measured in bio-
149 banked serum using the Cobas High-Sensitivity Immunoturbidimetric Assay (Roche
150 Diagnostics Limited, Burgess Hill, UK) per the manufacturer's [instructions](#).

151

152 *Microbiota analyses*

153 Pre-processing: Sequences were pre-processed using QIIME (version 2020.8)²⁰ and
154 DADA2²¹. Amplicon sequence variants (ASVs) were assigned at 99% similarity against
155 representative sequences in Greengenes (version 13.8)²² with zero abundance taxa
156 removed.

157 Taxonomic analyses: α - and β -diversities were calculated using *vegan* (v2.6-4)²³.
158 Differential taxa and pathway abundance analyses used *DESeq2* (v1.22.2)²⁴ with Benjamini-
159 Hochberg (BH) multiple testing correction after feature tables were pruned (genera not seen
160 >5 times in $\geq 1\%$ of samples removed)²⁵. CRP was categorised as high or low if the
161 concentration readout was above or below the median for the people included in that

162 analysis. Detailed methods for identifying potential contaminants and clustering analysis are
163 in the **Supplementary Material**.

164 Functional pathway analyses: Phylogenetic Investigation of Communities by
165 Reconstruction of Unobserved States (PICRUSt2; v.2.1.3-b)²⁶ was used for metagenomic
166 inference with default parameters (picrust2_pipeline.py) and metabolic function predictions
167 based on MetaCyc²⁷.

168 Correlation analysis with CRP and microbiome: Only sequence data with paired CRP
169 measurements were included. Microbial relative abundances were correlated with CRP
170 measurements using Correlations Under the Influence (CUTIE)²⁸.

171

172 *Statistical analyses*

173 Analyses used GraphPad Prism (v7; GraphPad Software, USA), STATA (v16; StataCorp,
174 USA) and R (v4.2; R Core Team). Medians with interquartile ranges (IQRs) were reported
175 for continuous variables, and the number and percentage were reported for categorical
176 variables. Non-parametric tests (microbiome data are not normally distributed²⁹) included the
177 Mann-Whitney or Wilcoxon signed-rank test for unpaired and paired comparisons involving
178 two groups, Kruskal-Wallis or Friedman tests for unpaired and paired comparisons involving
179 ≥ 2 groups, and Spearman's Rho for correlation analyses. Permutational multivariate analysis
180 of variance (PERMANOVA) was computed with 999 permutations for β -diversity, and R^2
181 used to measure variation explained by a variable. The Benjamini–Hochberg procedure was
182 used to correct for multiple comparisons by controlling the false discovery rate (FDR)²⁵.
183 Adjusted p -values of <0.2 and <0.05 were considered significant for taxa and pathways,
184 respectively³⁰. More information is in the **Supplementary Methods**.

185 **Results**

186 *Cohort characteristics*

187 Our cohort was comprised of 91 (65%), 25 (18%) and 23 (17%) dTBs, pTBs, and nTBs,
188 respectively (**Table 1**). Compared to nTBs, dTBs were more likely to have HIV, cough,
189 weight loss, be on medication (other than TB medication) and, in their PF, have lower
190 albumin but higher adenosine deaminase (ADA), lactate dehydrogenase (LDH), and
191 unstimulated interferon-gamma (uIFN- γ) concentrations. pTBs were more likely than nTBs to
192 have HIV, previous TB, and TB symptoms and, in PF, lower albumin and higher ADA and
193 uIFN- γ concentrations.

194

195 *Pericardial fluid shares few taxa with skin and background controls*

196 PF α -diversity was lower than background and skin. PF β -diversity differences occurred with
197 *Mycobacterium*- (vs. skin and background) and *Streptococcus*-enrichment (vs. skin only)
198 (**Figure S1A-D**). None of the top four potentially contaminating taxa identified appeared in
199 differential analyses (**Figures S2-3**, [additional table](#)).

200

201 *Mycobacterium and other potential opportunistic pathogens are enriched in dTBs*

202 Differences by TB status: We did not detect α -diversity differences (**Figure 2A**). β -
203 diversity differed between dTBs and pTBs, as well as pTBs vs. nTBs (PERMANOVA
204 $p=0.020$ and 0.003 , respectively, **Figure 2B**), but not between dTBs and nTBs. dTBs were
205 *Mycobacterium*-, *Lacticigenium*-, and *Kocuria*-enriched vs. nTBs (**Figure 2C**), and
206 *Mycobacterium*-, *Lacticigenium*- and *Caulobacter*-enriched and *Streptococcus*-depleted vs.
207 pTBs (**Figure 2D**). pTBs were *Streptococcus*- (vs. dTBs) and *Novosphingobium*-enriched vs.
208 nTBs (**Figure 2D-E**), and more phylogenetically dissimilar to each other. dTBs were the
209 most phylogenetically similar to each other followed by nTBs (**Figure S4**).

210 Grouping pTBs with dTBs or nTBs: When pTBs were grouped with dTBs or nTBs,
211 there were no α - or β -diversity differences vs. nTBs or dTBs, respectively (**Figure S5A-D**).

212 dTBs were *Mycobacterium*- and *Lacticigenium*-enriched vs. nTBs regardless of with whom
213 pTBs were grouped (**Figure S5E-F**).

214 16S rRNA gene sequencing correlates with diagnostic results: Mycobacterial reads
215 occurred in more dTBs than pTBs [34% (31/91) vs. 8% (2/25), $p=0.011$] but did not reach
216 significance when dTBs were compared to nTBs [17% (4/23), $p=0.181$] (**Figure 2F, Figure**
217 **S6**). Mycobacterial reads inversely correlated with PCR ($r=-0.361$, $p<0.012$; **Figure S7A**)
218 and culture measures of mycobacterial load ($r=-0.484$, $p<0.001$; **Figure S7B**).

219

220 *Bifidobacterium* enrichment is associated with HIV

221 Although α - and β -diversity did not differ by HIV status (**Figure S8A-B**), PLHIV were
222 *Mycobacterium*-enriched vs. HIV-negatives (**Figure S8C**).

223 Comparisons by HIV status within different TB groups: No α - and β -diversity
224 differences by HIV status occurred in dTBs or pTBs (**Table S2**). In dTBs, HIV-positives were
225 *Methylobacterium*-, *Bifidobacterium*-, and *Leptothrix*-enriched vs. HIV-negatives (**Figure**
226 **S8D**). nTBs were not compared by HIV status due to a small sample size (n=2 HIV-
227 positives).

228 Comparisons by TB status within people of the same HIV status: In HIV-positives, α -
229 diversity was similar by TB status (**Figure 3A**) but β -diversity differed ($p=0.038$; **Figure 3B**)
230 and dTBs were *Mycobacterium*-, *Bifidobacterium*-, and *Leptothrix*-enriched vs. pTBs (**Figure**
231 **3C**). α - and β -diversities were similar between HIV-positives with high vs. low CD4 counts
232 (dichotomised at median value, data not shown), where those with lower counts were
233 *Mycobacterium*-enriched vs. people with higher counts (**Figure S9A-B**). In HIV-negatives, α -
234 and β -diversities were similar between TB groups (**Figure 3D-E**) and taxonomic differences
235 were only observed between dTBs vs. pTBs, with dTBs *Kocuria*-, *Halomonas*-, and
236 *Gilvimirinus*-enriched (**Figure 3F**).

237 Comparisons by ART status in PLHIV: A third of PLHIV were on ART (**Table 1**). α -
238 Diversity was similar by ART status, but β -diversity differed (**Table S2**). Those on ART were

239 *Streptococcus*-enriched and *Mycobacterium*- and *Bifidobacterium*-depleted vs. those not on
240 ART (**Figure S9C**) and conclusions were similar when restricted to dTBs (**Figure S9D**).

241

242 *Chest abnormalities associated with the microbiome.*

243 We evaluated microbiome differences by CXR results (**Table 1**) and found no α -diversity
244 differences. However, β -diversity differed in people with vs. without pulmonary infiltrates
245 (PIs; **Table S2**), with people with PIs *Mycobacterium*-enriched and *Streptococcus*-depleted
246 (**Figure 4A**). β -diversity also differed in people with or without pleural effusions (PEs) (**Table**
247 **S2**), where people with PEs were *Streptococcus*- and *Pseudomonas*-enriched and
248 *Brachymonas*-depleted (**Figure 4B**).

249

250 *People with definite TBP are enriched in SCFA metabolic pathways.*

251 Compared to nTBs, dTBs were enriched with SCFA metabolism (*L-lysine fermentation to*
252 *acetate and butanoate*), aromatic compound degradation (*cinnamate and 3-*
253 *hydroxycinnamate degradation to 2-oxopent-4-enoate*), and mycobacterial metabolism
254 (*superpathway of mycolyl-arabinogalactan-peptidoglycan complex biosynthesis*) pathways
255 (**Figure 5**). Amongst dTBs, HIV-positives were depleted in biosynthesis pathways [*GDP-D-*
256 *glycero- α -D-manno-heptose biosynthesis*, *peptidoglycan biosynthesis V (β -lactam*
257 *resistance)* and *superpathway of geranylgeranyl diphosphate biosynthesis II (via MEP)*]
258 compared to HIV-negatives (**Figure S10**). Comparisons involving pTBs are in **Figures S11-**
259 **S12**.

260

261 *The association between CRP and the microbiome*

262 Microbial composition differed with *Pseudomonas* depleted in high vs. low CRP

263 CRP concentrations did not differ by TB status [median 137.30 (IQR 75.30 - 176.30) ng/mL
264 in dTBs vs. 95.96 (IQR 45.25 - 173.70) ng/mL in nTBs] (**Figure 6A**) nor correlated with
265 *Mycobacterium* reads (**Figure 6B-C**). People with above median CRP concentrations
266 [median 125.4 (IQR70.83 – 176.7) ng/mL] had, vs. those below the median, no α -diversity

267 differences (**Figure 6D**) but different β -diversity (**Figure 6E**), with *Pseudomonas*-depletion
268 (**Figure 6F**). These differences were similar when restricted to people of a specific TB
269 (**Table 2**) or HIV status (**Figures S13-14**), with a few additional taxa differentially enriched.
270 The top three taxa enriched in dTBs (*Mycobacterium*, *Lacticigenium*, *Kocuria*) did not
271 correlate with CRP levels (p-values of 0.523, 0.260, and 0.999, respectively).

272 Discussion

273 Our key findings are that 1) compared to PF from people without TBP, PF from people with
274 TBP differs both in terms of β -diversity and the relative abundance of specific taxa, including
275 those other than *Mycobacterium* (*Lacticigenium*, *Kocuria*, and *Weeksella*), 2) HIV is
276 associated with the differential abundance of *Mycobacterium* overall, and within dTBs,
277 *Bifidobacterium* is associated with proxies of more severe disease (HIV-positivity and, in
278 PLHIV, no ART), and 3) taxonomic differences between dTBs and nTBs manifest in different
279 functional capacities, including enrichment of SCFA production pathways. Furthermore, 4)
280 the PF microbiome is associated with distinctive clinical and chest imaging characteristics
281 and 5) many people with dTB do not have PF *Mycobacterium* reads whereas some people
282 without dTB have *Mycobacterium* reads, 6) CRP did not differ by TB status or HIV status,
283 and α -diversity was similar by CRP status, however, β -diversity differed, with *Pseudomonas*
284 enrichment in people with low (vs. high) CRP. This is the first characterisations of the site-of-
285 disease microbiome in people with pericarditis, specifically in a high TB HIV-endemic setting.
286

287 dTBs were enriched in several taxa in addition to *Mycobacterium*. These include *Kocuria*, a
288 skin commensal that causes an infection of the heart e.g., native valve endocarditis, albeit
289 rarely³¹, and *Weeksella* which can also cause serious bacterial infections like bacteraemia,
290 and spontaneous bacterial peritonitis³². The relevance of these taxa in TBP requires further
291 investigation.

292

293 *Mycobacterium* was enriched in PLHIV compared to people without HIV. Furthermore,
294 *Bifidobacterium* was associated with clinical features characteristic of severe disease (HIV-
295 positivity and, in those with HIV, no ART and lower CD4 counts. *Bifidobacterium*, while
296 commonly considered a beneficial, immunomodulatory gut commensal³³, has been
297 described as either depleted^{9 34} or enriched^{35 36} in people with pulmonary TB compared to
298 symptomatic controls. However, our findings are consistent with the latter. *Bifidobacterium*

299 can act opportunistically, causing bacteraemia in immunocompromised people and those
300 with a damaged intestinal barrier³⁷.

301

302 Similar to previous work involving people with different forms of TB (i.e., pulmonary TB and
303 TB lymphadenitis³⁸), people with TBP were enriched in SCFA-producing bacteria (e.g.,
304 *Lacticigenium* produces acetic and lactic acid) and pathways (*L-lysine fermentation to*
305 *acetate and butanoate*, amino acid and carbohydrate metabolism butyrate precursor
306 pathways)^{39 40}. dTBs also had elevated PF concentrations of LDH, a marker of tissue
307 damage, however we acknowledge that it could include microbially-derived LDH. Lactate
308 metabolism is also important for *Mtb* growth⁴¹

309

310 Furthermore, HIV-positive dTBs not on ART are, in addition to *Mycobacterium*, enriched in
311 *Bifidobacterium*, a known producer of lactate which itself is also an intermediate metabolite
312 of the butyrate biosynthetic pathway^{42 43}. Butyrate suppresses protective host responses
313 (IFN- γ and IL-17A) to *Mtb*. Future studies should evaluate whether enhanced site-of-disease
314 SCFA production correlates with both local and peripheral inflammation.

315

316 Pericarditis is often associated with pulmonary parenchymal disease. Notably, the PF
317 microbiome was associated with a greater probability of chest imaging characteristics where
318 individuals with PI showed distinct PF β -diversity compared to those without, characterized
319 by increased *Mycobacterium* (likely resulting from more direct contact with the route of
320 infection and site of pulmonary disease) and reduced *Streptococcus*. Similarly, individuals
321 with pleural effusion exhibited different PF β -diversity compared to those without, with higher
322 levels of *Streptococcus* and lower levels of *Brachymonas*. Pulmonary infiltrates are
323 commonly observed in radiological imaging of individuals with pulmonary TB⁴⁴, while pleural
324 effusions are predominantly caused by TB in developing countries⁴⁵. Consequently,
325 obtaining sputum cultures and Xpert tests is crucial in suspected cases of TBP, even when
326 parenchymal involvement is not evident. Furthermore, the co-existence of these features

327 may reflect the TB route from the lungs to the heart, and what taxa might accompany that
328 spread.

329

330 People within each TB group had *Mtb* DNA detected. The reasons for this are likely
331 multifaceted: primarily due to technical methodological limitations (metagenomic sequencing
332 would have more discriminatory power for species within *Mycobacteria*) but could also be
333 due to TB exposure, past infection, TB disease at another anatomical site, or cross-
334 contamination. It is important to note that 66% of dTBs did not show *Mycobacterium*
335 readings, likely due to the limited sensitivity of 16S rRNA sequencing for detecting this
336 genus, whose cells often lyse and release DNA inefficiently and may be biased against by
337 conventional sequencing approaches (a “mycobacteriome” approach could be used to study
338 mycobacterial diversity further)⁴⁶.

339

340 CRP is a commonly studied biomarker in TB, and during active TB infection, CRP levels
341 tend to be elevated due to the body's immune response to the mycobacterial infection⁴⁷.
342 Similarly, CRP levels can be elevated in individuals with HIV because HIV infection is
343 associated with chronic inflammation and immune activation, particularly in those with
344 advanced disease or opportunistic infections⁴⁸⁻⁵⁰. However, in our study, unlike previously
345 reported studies⁵¹⁻⁵³, the level of CRP, appears to not be influenced by the presence of
346 active TB in TBP. Despite this, the median CRP value in our TBP cohort 125.4 (70.83 –
347 176.70) ng/mL exceeded the diagnostic threshold⁵⁴ for TB diagnosis. This observation can
348 be attributed to the fact our study only included people that were suspected to have TPB,
349 leading to the presence of specific clinical symptoms and some form of the disease,
350 regardless of whether it was TB or another condition. As a result, this could have contributed
351 to the elevated CRP levels to some extent. Notably, we observed a depletion of
352 *Pseudomonas* in presumptive TBP people with high CRP compared to those with low CRP,
353 similar to a report of an adverse relationship between sputum genus richness and CRP in
354 bronchiectasis^{55 56}.

355

356 The study has strengths and limitations. DNA-based sequencing was employed to analyze
357 microbial communities, and alternative methods like culturomics, metagenomics, or
358 metatranscriptomics may yield different results. Furthermore, as our study was nested within
359 TB care at our hospital, our study data were influenced by limitations in routinely available
360 data (e.g., unknown ART duration); however, this allowed us to recruit a high number of
361 people. We also did background sampling and sequencing to detect potential cross-
362 contamination of our low biomass fluid (PF), which allowed us to confirm that none of the
363 discriminatory taxa identified in our analyses likely resulted from contamination. The study
364 used a relaxed FDR-adjusted p-value threshold of 0.2 to identify various taxa, prioritizing
365 hypothesis generation. This threshold was chosen as lower thresholds did not yield
366 significant taxa, underscoring the need for broader exploration. We do not know which
367 microbes are driving the high CRP in TB, however, this study was not designed to
368 investigate this, and further studies would be required. We acknowledge the non-specificity
369 of CRP as a general marker of inflammation. Finally, this study is a cross-sectional study, so
370 it's unable to establish temporal relationships.

371

372 In summary, the microbiomes of people with TBP (including those co-infected with HIV) are
373 different to people without TBP and characterised by enriched *Mycobacterium* and other
374 potentially immunomodulatory bacteria (*Bifidobacterium*, *Lacticigenium*). Further research is
375 needed to define these mechanistic relationships (e.g., through murine models), including
376 how the microbiota is altered by treatment and its association, if any, with clinical outcomes.
377 This will provide insights into the development of effective host-directed therapies for TBP.

378 **Funding**

379 This work and authors were supported by the European & Developing Countries Clinical
380 Trials Partnership (EDCTP; project numbers SF1041, TMA2019CDF-2738-ESKAPE-TB),
381 National Research Foundation, South African Medical Research Council (SAMRC), Harry
382 Crossley Foundation and Stellenbosch University Faculty of Health Sciences. We also
383 acknowledge funding from Veterans Affairs (IK2BX005309-01A2) and the National Institutes
384 of Health under award number KL2TR001446, and CHEST Foundation Research Grant in
385 Chronic Obstructive Pulmonary Disease. CCN and GT acknowledge funding from the
386 National Institutes of Health under award numbers K43TW012302 and R01AI136894. GRN
387 acknowledges funding from L'Oréal-UNESCO For Women in Science Sub-Saharan Africa
388 Young Talents Award, and the International Rising Talents Award. The content is the solely
389 the responsibility of the authors and does not necessarily represent the official views of the
390 funders.

391

392 **Acknowledgments**

393 The authors thank all study participants and CLIME staff, especially Sr Ruth Wilson.
394 Computations were performed using facilities provided by the University of Cape Town's
395 ICTS High Performance Computing team: hpc.uct.ac.za.

396

397 **Conflict of Interest**

398 The other authors each declare no competing interests.

399

400 **References**

- 401 1. World Health Organization. Global Tuberculosis Report 2022. Geneva, Switzerland, 2022.
- 402 2. Gupta RK, Lawn SD, Bekker L-G, et al. Impact of human immunodeficiency virus and
403 CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South
404 Africa. *The international journal of tuberculosis and lung disease* 2013;17(8):1014-22.

- 405 3. Leeds IL, Magee MJ, Kurbatova EV, et al. Site of extrapulmonary tuberculosis is
406 associated with HIV infection. *2012*;55(1):75-81.
- 407 4. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. *Circulation*
408 2005;112(23):3608-16.
- 409 5. Noubiap JJ, Agbor VN, Ndoadoumgue AL, et al. Epidemiology of pericardial diseases in
410 Africa: a systematic scoping review. *Heart* 2019;105(3):180-88.
- 411 6. Mayosi BM, Wiysonge CS, Ntsekhe M, et al. Mortality in patients treated for tuberculous
412 pericarditis in sub-Saharan Africa. *S Afr Med J* 2008;98(1):36-40.
- 413 7. Somboro AM, Diallo D, Holl JL, Maiga M. The role of the microbiome in inflammation
414 during tuberculosis. *EBioMedicine* 2021;68
- 415 8. Mori G, Morrison M, Blumenthal A. Microbiome-immune interactions in tuberculosis. *PLoS*
416 *Pathogens* 2021;17(4):e1009377.
- 417 9. Naidoo CC, Nyawo GR, Sulaiman I, et al. Anaerobe-enriched gut microbiota predicts pro-
418 inflammatory responses in pulmonary tuberculosis. *EBioMedicine* 2021;67:103374.
- 419 10. Naidoo CC, Nyawo GR, Wu BG, et al. The microbiome and tuberculosis: state of the art,
420 potential applications, and defining the clinical research agenda. *Lancet Respir Med*
421 2019;7(10):892-906. doi: 10.1016/S2213-2600(18)30501-0 [published Online First:
422 20190322]
- 423 11. Segal LN, Clemente JC, Li Y, et al. Anaerobic Bacterial Fermentation Products Increase
424 Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients. *Cell host & microbe*
425 2017;21(4):530-37 e4. doi: 10.1016/j.chom.2017.03.003
- 426 12. Du Clos TW. Function of C-reactive protein. *Annals of medicine* 2000;32(4):274-78.
- 427 13. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2:
428 screening-systematic screening for tuberculosis disease. Geneva, Switzerland: World
429 Health Organization 2021.
- 430 14. Ma W, Nguyen LH, Song M, et al. Dietary fiber intake, the gut microbiome, and chronic
431 systemic inflammation in a cohort of adult men. *Genome medicine* 2021;13(1):102.

- 432 15. Furet J-P, Kong L-C, Tap J, et al. Differential adaptation of human gut microbiota to
433 bariatric surgery–induced weight loss: links with metabolic and low-grade inflammation
434 markers. *Diabetes* 2010;59(12):3049-57.
- 435 16. Rajkumar H, Mahmood N, Kumar M, et al. Effect of probiotic (VSL# 3) and omega-3 on
436 lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight
437 adults: a randomized, controlled trial. *Mediators Inflamm* 2014;2014
- 438 17. Petakh P, Kobyljak N, Kamyshnyi A. Gut microbiota in patients with COVID-19 and type
439 2 diabetes: A culture-based method. *Frontiers in Cellular and Infection Microbiology*
440 2023;13:108.
- 441 18. Nyawo GR, Naidoo CC, Wu B, et al. More than Mycobacterium tuberculosis: site-of-
442 disease microbial communities, and their functional and clinical profiles in tuberculous
443 lymphadenitis. *Thorax* 2023;78(3):297-308.
- 444 19. Reuter H, Burgess L, van Vuuren W, Doubell A. Diagnosing tuberculous pericarditis.
445 *QJM: An International Journal of Medicine* 2006;99(12):827-39. doi:
446 10.1093/qjmed/hcl123
- 447 20. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible
448 microbiome data science using QIIME 2. *Nature biotechnology* 2019;37(8):852-57.
- 449 21. Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: high-resolution sample inference
450 from Illumina amplicon data. *Nature methods* 2016;13(7):581-83.
- 451 22. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with
452 explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *The ISME*
453 *journal* 2012;6(3):610.
- 454 23. Dixon P. VEGAN, a package of R functions for community ecology. *Journal of*
455 *Vegetation Science* 2003;14(6):927-30.
- 456 24. McMurdie PJ, Holmes S. Waste not, want not: why rarefying microbiome data is
457 inadmissible. *PLoS computational biology* 2014;10(4)
- 458 25. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false
459 discovery rate controlling procedures. *Bioinformatics* 2003;19(3):368-75.

- 460 26. Douglas GM, Maffei VJ, Zaneveld J, et al. PICRUSt2: An improved and customizable
461 approach for metagenome inference. *BioRxiv* 2020:672295.
- 462 27. Caspi R, Altman T, Billington R, et al. The MetaCyc database of metabolic pathways and
463 enzymes and the BioCyc collection of Pathway/Genome Databases. *Nucleic Acids Res*
464 2014;42(D1):D459-D71.
- 465 28. Bu K, Wallach DS, Wilson Z, et al. Identifying correlations driven by influential
466 observations in large datasets. *Briefings in Bioinformatics* 2022;23(1):bbab482.
- 467 29. Estaki M, Jiang L, Bokulich NA, et al. QIIME 2 Enables Comprehensive End-to-End
468 Analysis of Diverse Microbiome Data and Comparative Studies with Publicly Available
469 Data. *Current protocols in bioinformatics* 2020;70(1):e100.
- 470 30. Seumois G, Zapardiel-Gonzalo J, White B, et al. Transcriptional profiling of Th2 cells
471 identifies pathogenic features associated with asthma. *The Journal of Immunology*
472 2016;197(2):655-64.
- 473 31. Kandi V, Palange P, Vaish R, et al. Emerging bacterial infection: identification and
474 clinical significance of *Kocuria* species. *Cureus* 2016;8(8)
- 475 32. Campbell IM, Congdon M, Capucilli PS, Fox WW. A Not So Common Infection in an
476 Extremely Low-Birth-Weight Infant. *Clinical Pediatrics* 2020;59(11):1040-42.
- 477 33. Lokesh D, Parkesh R, Kammara R. *Bifidobacterium adolescentis* is intrinsically resistant
478 to antitubercular drugs. *Scientific reports* 2018;8(1):11897.
- 479 34. Baral T, Kurian SJ, Thomas L, et al. Impact of tuberculosis disease on human gut
480 microbiota: a systematic review. *Expert Review of Anti-infective Therapy* 2023(just-
481 accepted)
- 482 35. Khaliq A, Ravindran R, Afzal S, et al. Gut microbiome dysbiosis and correlation with
483 blood biomarkers in active-tuberculosis in endemic setting. *PloS one*
484 2021;16(1):e0245534.
- 485 36. Wang Y, Deng Y, Liu N, et al. Alterations in the Gut Microbiome of Individuals With
486 Tuberculosis of Different Disease States. *Frontiers in Cellular and Infection Microbiology*
487 2022:328.

- 488 37. Esaiassen E, Hjerde E, Cavanagh JP, et al. Bifidobacterium bacteremia: clinical
489 characteristics and a genomic approach to assess pathogenicity. *Journal of clinical*
490 *microbiology* 2017;55(7):2234-48.
- 491 38. Nyawo GG, Naidoo CC, Wu B, et al. More than Mycobacterium tuberculosis: specific
492 site-of-disease microbial communities, functional capacities, and their distinct clinical
493 profiles in tuberculous lymphadenitis. *bioRxiv* 2022
- 494 39. Schillinger U, Endo A. Minor genera of the Carnobacteriaceae: Allofustis, Alloiococcus,
495 Atopobacter, Atopococcus, Atopostipes, Bavariococcus, Desemzia, Dolosigranulum,
496 Granulicatella, Isobaculum and Lacticigenium. *Lactic Acid Bacteria: Biodiversity and*
497 *Taxonomy* 2014:159-70.
- 498 40. Iino T, Suzuki K-i, Harayama S. Lacticigenium naphthae gen. nov., sp. nov., a halotolerant
499 and motile lactic acid bacterium isolated from crude oil. *International journal of systematic*
500 *and evolutionary microbiology* 2009;59(4):775-80.
- 501 41. Billig S, Schneefeld M, Huber C, et al. Lactate oxidation facilitates growth of
502 Mycobacterium tuberculosis in human macrophages. *Scientific reports* 2017;7(1):1-12.
- 503 42. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host
504 physiology: short-chain fatty acids as key bacterial metabolites. *Cell* 2016;165(6):1332-
505 45.
- 506 43. Baxter NT, Schmidt AW, Venkataraman A, et al. Dynamics of human gut microbiota and
507 short-chain fatty acids in response to dietary interventions with three fermentable fibers.
508 *mBio* 2019;10(1):e02566-18.
- 509 44. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical
510 review. *Tuberculosis* 2011;91(6):497-509.
- 511 45. Light RW. Update on tuberculous pleural effusion. *Respirology* 2010;15(3):451-58.
- 512 46. Thornton CS, Mellett M, Jarand J, et al. The respiratory microbiome and nontuberculous
513 mycobacteria: an emerging concern in human health. *European Respiratory Review*
514 2021;30(160)

- 515 47. Wilson D, Badri M, Maartens G. Performance of serum C-reactive protein as a screening
516 test for smear-negative tuberculosis in an ambulatory high HIV prevalence population.
517 *PLoS ONE* 2011;6(1):e15248.
- 518 48. Sage E, Noursadeghi M, Evans H, et al. Prognostic value of C-reactive protein in HIV-
519 infected patients with *Pneumocystis jirovecii* pneumonia. *International journal of STD &*
520 *AIDS* 2010;21(4):288-92.
- 521 49. Boulware DR, Hullsiek KH, Puroden CE, et al. Higher levels of CRP, D-dimer, IL-6, and
522 hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with
523 increased risk of AIDS or death. *Journal of Infectious Diseases* 2011;203(11):1637-46.
- 524 50. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum C-
525 reactive protein for screening for HIV-associated tuberculosis. *The International journal of*
526 *tuberculosis and lung disease* 2013;17(5):636-43.
- 527 51. Ciccacci F, Florida M, Bernardini R, et al. Plasma levels of CRP, neopterin and IP-10 in
528 HIV-infected individuals with and without pulmonary tuberculosis. *Journal of Clinical*
529 *Tuberculosis and Other Mycobacterial Diseases* 2019;16:100107.
- 530 52. Liu H, Zheng R, Wang P, et al. IL-37 confers protection against mycobacterial infection
531 involving suppressing inflammation and modulating T cell activation. *PLoS ONE*
532 2017;12(1):e0169922.
- 533 53. Steingart KR, Schiller I, Horne DJ, et al. Xpert® MTB/RIF assay for pulmonary
534 tuberculosis and rifampicin resistance in adults. *Cochrane database of systematic*
535 *reviews* 2014(1)
- 536 54. Yoon C, Semitala FC, Atuhumuza E, et al. Point-of-care C-reactive protein-based
537 tuberculosis screening for people living with HIV: a diagnostic accuracy study. *The Lancet*
538 *Infectious Diseases* 2017;17(12):1285-92.
- 539 55. Rogers GB, Zain NMM, Bruce KD, et al. A novel microbiota stratification system predicts
540 future exacerbations in bronchiectasis. *Annals of the American Thoracic Society*
541 2014;11(4):496-503.

542 56. Richardson H, Dicker AJ, Barclay H, Chalmers JD. The microbiome in bronchiectasis.

543 *European Respiratory Review* 2019;28(153)

544

545 **Data availability**

546 Data and code will be made available upon publication. Other supporting data are available

547 from the corresponding author (GT) on reasonable request.

548 **Table 1: Demographic and clinical characteristics of people with presumptive TB**
 549 **pericarditis. dTBs were more likely to have HIV, cough, weigh less, be using non-TB**
 550 **medications and, in PF, have lower albumin concentrations and higher ADA, LDH, and**
 551 **uIFN- γ concentrations than nTBs. pTBs were more likely to have HIV, previous TB,**
 552 **more self-reported symptoms, have lower albumin concentration, and have higher**
 553 **ADA and uIFN- γ fluid concentration, than nTBs. dTBs were less likely to already be on**
 554 **treatment at recruitment (< 2 weeks) compared to pTBs. Data are n/N (%) or median**
 555 **(IQR).**

	People with presumptive TB				<i>p-value</i>		
	Total (n=139)	dTB (n=91)	pTB (n=25)	nTB (n=23)	dTB vs. pTB	dTB vs. nTB	pTB vs. nTB
Age, years	37 (31, 48)	40 (31, 48)	34 (31, 46)	37 (31, 58)	0.910	0.563	0.485
Sex (Female)	59/139 (42)	37/91 (41)	10/25 (40)	12/23 (52)	>0.999	0.450	0.580
Current tobacco smoker	30/138 (22)	17/90 (19)	6/25 (24)	7/23 (30)	0.780	0.360	0.860
Previous tobacco smoker	29/108 (27)	19/73 (26)	7/19 (37)	3/16 (19)	0.370	0.950	0.420
Clinical characteristics:							
HIV	75/139 (54)	53/91 (58)	20/25 (80)	2/23 (9)	0.046	<0.0001	<0.0001
On ART	26/73 (37)	18/53 (34)	7/18 (39)	1/2 (50)	0.930	>0.999	>0.999
CD4 count, cells/ μ l	158 (54, 319)	151 (49, 328)	208 (97, 339)	106 (36, 176)	>0.999	>0.999	0.971
Previous TB	31/136 (23)	21/88 (24)	9/25 (36)	1/23 (4)	0.339	0.072	0.019
Self-reported symptoms:							
Cough	76/132 (58)	52/85 (61)	16/24 (67)	8/23 (35)	0.801	0.043	0.058
Fever	52/131 (40)	35/85 (41)	12/23 (52)	5/23 (22)	0.480	0.142	0.067
Night sweats	68/133 (51)	45/86 (52)	15/24 (63)	8/23 (35)	0.510	0.210	0.110
Weight loss	85/134 (63)	60/87 (69)	17/24 (71)	8/23 (35)	>0.999	0.006	0.029
Chest X-ray results:							
Cardiomegaly	93/139 (67)	61/91 (67)	17/25 (68)	15/23 (65)	>0.999	>0.999	>0.999
Pulmonary infiltrates	31/139 (22)	23/91 (25)	4/25 (16)	4/23 (17)	0.480	0.600	>0.999
Hilar lymphadenopathy	11/139 (8)	7/91 (8)	2/25 (8)	2/23 (9)	>0.999	>0.999	>0.999
Miliary pattern	7/139 (5)	6/91 (7)	1/25 (4)	0/23 (0)	0.990	0.460	>0.999
Pleural effusion	88/139 (63)	60/91 (66)	16/25 (64)	12/23 (52)	>0.999	0.330	0.590
Pericardial tamponade	47/127 (37)	29/81 (36)	9/23 (39)	9/23 (39)	0.960	0.960	>0.999
Treatment history:							
Current TB treatment (<2 weeks)	21/139 (15)	12/91 (13)	9/25 (36)	0/23 (0)	0.020	0.144	0.005
No TB treatment	118/139 (85)	79/91 (87)	16/25 (64)	23/23 (100)	0.020	0.144	0.005
Other medications	58/129 (45)	33/83 (40)	9/23 (39)	16/23 (70)	>0.999	0.210	0.076
Non-TB antibiotic use within 1 year	21/125 (17)	12/80 (15)	7/24 (29)	2/17 (12)	0.200	>0.999	0.350
Current non-TB antibiotic use	17/21 (81)	10/12 (83)	5/7 (71)	2/2 (100)	0.980	>0.999	>0.999
Total volume aspirated (mL)	700 (500, 1000)	670 (500, 915)	720 (500, 1000)	750 (400, 1050)	>0.999	>0.999	>0.999
Fluid cytochemistry:							
ADA (U/L)	48 (26, 67)	51 (34, 68)	50 (38, 65)	16 (11, 33)	>0.999	0.001	0.016
Protein (g/L)	58 (50, 65)	58 (49, 64)	61 (55, 67)	60 (50, 64)	>0.999	>0.999	>0.999
LDH (g/L)	696 (424, 1440)	840 (451, 1440)	645 (541, 1490)	408 (181, 842)	>0.999	0.016	0.132

Albumin (U/L)	22 (16, 26)	21 (16, 25)	23 (19, 26)	28 (25, 30)	>0.999	0.010	0.126
uIFN- γ (pg/mL)	803 (3, 2510)	1150 (165, 2590)	885 (4, 2810)	28 (0, 5)	>0.999	<0.0001	<0.0001
Blood CRP (mg/L)*	125 (71, 177)	137 (75, 176)	136 (93, 202)	96 (45, 174)	>0.999	>0.999	>0.999
Mortality	24 (18)	14/88 (16)	4/24 (17)	6/22 (27)	>0.999	0.350	0.610

556 *For CRP, paired samples were available from 112/139 participants (72/91 dTB; 20/25 pTB and 20/23 nTB). Missing data:

557 Current tobacco smoker (n=1), Previous tobacco smoker (n=31), ART status (n=2), Previous TB (n=3), Self-reported symptoms

558 (n=8), Other medications (n=10), Non-TB antibiotic use within 1 year (n=14). Bold indicates statistical significance (P < 0.05).

559 Abbreviations: ADA: adenosine deaminase; ART: antiretroviral therapy; CRP: C-reactive protein; dTB: definite tuberculous

560 pericarditis; IQR: interquartile range; LDH: lactate dehydrogenase; nTB: non-tuberculous pericarditis; pTB: probable

561 tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis; and uIFN- γ : unstimulated interferon gamma

562 **Table 2: CRP levels do not affect microbiome α -diversity, but influence β -diversity in**
 563 **people with presumptive TBP. α -diversity remained consistent regardless of CRP**
 564 **concentration, while significant differences in β -diversity were observed, indicating**
 565 **distinct microbial compositions between the two groups.**

High vs. low CRP	Overall (n=139)			dTb (n=91)			pTb (n=25)			nTb (n=23)		
	α -diversity	β -diversity		α -diversity	β -diversity		α -diversity	β -diversity		α -diversity	β -diversity	
		<i>p</i> -value	<i>R</i> ² value		<i>p</i> -value	<i>R</i> ² value		<i>p</i> -value	<i>R</i> ² value		<i>p</i> -value	<i>R</i> ² value
All participants	0.982	0.015	0.02723	0.982	0.013	0.02723	0.2265	0.527	0.0461	0.5967	0.3333	0.04407
Within HIV-positives	0.8932	0.059	0.02537	0.5028	0.05	0.03891	0.6744	0.826	0.04857	0.3173	-	-
Within HIV-negatives	0.1432	0.526	0.01987	0.2282	0.719	0.03419	0.1213	0.3333	0.36901	0.6911	0.668	0.04903

Bold indicates statistical significance ($P < 0.05$). Abbreviations: CRP: C-reactive protein; dTb: definite tuberculous pericarditis; nTb: non-tuberculous pericarditis; pTb: probable tuberculous pericarditis; Tb: tuberculosis.

566 **Figure legends**

567

568 **Figure 1: Study flow chart.** Pericardial fluid, skin and background controls were collected
569 from 140 presumptive TBP people. dTBs: definite tuberculous pericarditis; nTBs: non-
570 tuberculous pericarditis; pTBs: probable tuberculous pericarditis; Smear: Smear microscopy;
571 MGIT960 Culture: Mycobacteria Growth Indicator Tube 960 liquid culture; Xpert: Xpert
572 MTB/RIF; Ultra: Xpert MTB/RIF Ultra.

573

574 **Figure 2: dTBs have a distinct microbiome enriched in *Mycobacterium* and other**
575 **potential opportunistic pathogens. (A)** Although α -diversity, which measures species
576 diversity, was similar across the three groups, **(B)** β -diversity, which measures differences in
577 microbial composition, differed significantly between PF microbiota of pTBs vs. dTBs and
578 pTBs vs. nTBs. **(C)** dTBs vs. nTBs were *Mycobacterium*-, *Lacticigenium*- and *Kocuria*-
579 enriched, and *Streptococcus*-depleted. **(D)** dTBs vs. pTBs were *Mycobacterium*-,
580 *Lacticigenium*-, and *Caulobacter*-enriched and *Streptococcus*-depleted. **(E)** pTBs vs. nTBs
581 were *Novosphingobium*- and *Streptococcus*-enriched (red dotted line represents adjusted p -
582 value=0.2; circle size represents relative abundance; taxa identified as possible
583 contaminants are shown in grey). **(F)** Genus-level average relative abundances of top taxa
584 differentiating between TB groups. dTB: definite tuberculous pericarditis; nTB: non-
585 tuberculous pericarditis; PF: pericardial fluid; pTB: probable tuberculous pericarditis; TB:
586 tuberculosis; TBP: tuberculous pericarditis.

587

588 **Figure 3: *Bifidobacterium* enrichment is associated with *Mycobacterium* and HIV**
589 **positivity in TBP.** In PLHIV, **(A)** α -diversity did not differ by TB status, **(B)** however, β -
590 diversity did, **(C)** where HIV-positive dTBs were *Mycobacterium*-, *Bifidobacterium*-, and
591 *Leptothrix*-enriched, and *Streptococcus*-depleted compared to HIV-positive pTBs. In people
592 without HIV, both **(D)** α -diversity and **(F)** β -diversity did not differ by TB status, and HIV-
593 negative dTBs were *Mycobacterium*, *Caulobacter*, and *Weeksellia*-enriched, and

594 *Streptococcus*-depleted compared to HIV-negative pTBs (red dotted line represents adjusted
595 p -value=0.2; circle size represents relative abundance; taxa identified as possible
596 contaminants are shown in grey). dTB: definite tuberculous pericarditis; HIV+: HIV-positive;
597 HIV-: HIV-negative; nTB: non- tuberculous pericarditis; PF: pericardial fluid; pTB: probable
598 tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis

599

600 **Figure 4: Correlations between imaging and clinical characteristics and the PF**

601 **microbiota.** Pulmonary infiltrates (PI) and pleural effusions (PE) are associated with PF
602 microbiome. Compared to patients without PI, **(A)** presumptive TBPs with a PI were
603 *Mycobacterium*-enriched and *Lactigenium*- and *Streptococcus*-depleted, whilst **(B)**
604 compared to patients without PE, presumptive TBP people with PE were *Streptococcus*- and
605 *Pseudomonas*-enriched, and *Brachymonas*-depleted (red dotted line represents adjusted p -
606 value=0.2; circle size represents relative abundance; taxa identified as possible
607 contaminants are shown in grey). dTB: definite tuberculous pericarditis; PF: pericardial
608 fluid; PE: pleural effusions; PI: pulmonary infiltrates; pTB: probable tuberculous pericarditis;
609 TB: tuberculosis; TBP: tuberculous pericarditis

610

611 **Figure 5: Inferred functional content shows enrichment of SCFA metabolic pathways**

612 **in the PF of TBP.** PF in dTBs infer a distinct functional capacity, including an enrichment of
613 pathways associated with the production of short-chain fatty acids (SCFAs), aromatic
614 compound degradation, and mycobacterial metabolism vs. nTBs (red dotted line represents
615 adjusted p -value=0.05; circle size represents relative abundance; pathways of interest are
616 bolded). dTB: definite tuberculous pericarditis; PF: pericardial fluid; nTB: non-tuberculous
617 pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis; SCFA: short chain fatty acids.


618

619 **Figure 6: Microbial composition differs in presumptive TBP people with high vs low**

620 **CRP.**

621 **A)** CRP levels are similar in dTBs vs. pTBs vs. nTBs. **B)** Mycobacterial reads do not
622 correlate with CRP levels; r_s represents the Spearman's Rho coefficient for the correlation of
623 mycobacterial reads with CRP. People with high CRP levels have similar **C)** *Mycobacterium*
624 reads and **D)** α -diversity in their pericardial fluid compared to people with low CRP levels
625 (solid circles: dTB; empty squares: pTB; empty circles: nTB). **E)** β -diversity differs between
626 people with high vs low CRP. **F)** *Pseudomonas* is depleted in people with high vs low CRP.
627 Discriminatory taxa appear above the threshold (red dotted line, FDR=0.2); circle size
628 represents relative abundance. CI, Confidence interval; CRP, C-reactive protein; dTB:
629 definite-TBP; FDR, false discovery rate; nTBP, non-TBP; PERMANOVA, permutational
630 multivariate analysis of variance; pTB: probable-TBP; TBP: tuberculous pericarditis.

Figure 1.



Samples from 140 people were randomly rarefied to a depth of 1821 features and one sample with insufficient depth was excluded, leaving samples from 139 people.

Abbreviations: ART: antiretroviral therapy; dTB: definite tuberculous pericarditis; MGIT960 culture: mycobacteria growth indicator tube 960 liquid culture; nTB: non-tuberculous pericarditis; pTB: probable tuberculous pericarditis; Smear: Smear microscopy; Ultra: Xpert MTB/RIF Ultra; Xpert: Xpert MTB/RIF; TB: tuberculosis; TBP: tuberculous pericarditis.

Figure 2.




Figure 3.




Figure 4.




Figure 5.




Figure 6.

